spacer
home > pmps > autumn 2017 > cross-over tech
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Cross-Over Tech

Therapies to treat respiratory diseases account for about 10% of the global pharmaceutical market. Specialised devices and technologies exist to efficiently deliver drugs to treat respiratory diseases. Pressurised aerosol metered dose inhalers were first introduced in the 1950s; these were then followed in the 1960s and 70s by dry powder inhalers (DPIs) and nebulisers. In one form or another, they have been around for several decades. Finding technical solutions to the many challenges associated with these drug delivery technologies can be difficult. Technical solutions can be sought by looking at how such challenges were overcome in adjacent drug delivery areas, such as injectables and nasal drug delivery devices.

Respiratory Technologies


Since metered dose inhaler devices (MDI) were originally introduced in 1956, and since DPIs first reached the marketplace in the 1960s, inhalation device technology has seen significant advances in the last 60 years. Some of these innovations in the administration of inhaled drugs and how these advances have already been or could be applied to delivery systems in other related drug delivery fields will be looked at. Additionally, the reverse how technology from other drug delivery fields, such as nasal and injectable devices, have already impacted or could impact respiratory drug delivery will also be considered. Technical challenges, all the way from age-old concerns such as toxicological issues to modern day advances such as connected technologies, will be discussed.

Innovative Materials

The injectables field can provide interesting technical solutions to meet respiratory technological challenges. One such example is the use of cyclic olefin copolymer elastomers (COCe), a material well-known and used in the injectables industry and other pharmaceutical applications (1). A list of attractive features such as sealing efficiency, moisture resistance and cleanliness make it an excellent candidate for static gasket sealing systems for MDIs. This technology has now been developed to industrial-scale for use in inhalation devices and is a good example of cross-over technology between different application fields. COCe as an innovative sealing material can offer several advantages to the overall stability and performance of MDI products incorporating this kind of valve-to-canister sealing technology.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Gerallt Williams is Director of Scientific Affairs at Aptar Pharma, France. After obtaining his PhD from the University of Wales, UK, in 1985, he has held various industrial positions at Monsanto and Fisons in the UK, Valois in France and Inhale/Nektar Therapeutics in the US. He is now in charge of scientific affairs for the Aptar Pharma Prescription Division, Le Vaudreuil, France, and is engaged in the development of new devices for nasal, inhaled and injectable drug products. 
spacer
Dr Gerallt Williams
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific
More info >>

White Papers

Streamlining patient recruitment using EHR data

The field of (bio)pharmaceutical research is booming. Increasingly more innovative therapeutics are being developed with the ability to drastically improve the quality of life of millions of patients around the world. Rigorously testing each of these candidate drugs for their safety and efficacy is an essential part of the development process. As the number of clinical trials steadily increases, the search for patients who present a specific medical profile and are willing to participate intensifies.
More info >>

 
Industry Events

ASGCT 22nd Annual Meeting

29 April - 2 May 2019, Washington Hilton, Washington, D.C

The 2019 ASGCT Annual Meeting is expected to be the largest in Society history, eclipsing the mark set by the 2018 meeting just last year. Join more than 3,500 researchers, clinicians, advocates, and industry leaders in discovering the latest science and technology surrounding gene and cell therapy.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement